ReviewInternational journal of urology : official journal of the Japanese Urological Association2013
Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.
Review in International journal of urology : official journal of the Japanese Urological Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02981459 (Pilot Study), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study: Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women, an Open Label Study With Dose Escalation
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Overactive bladder - 18 years - Part II.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Oxidative Stress and Its Relation to Lower Urinary Tract Symptoms.International neurourology journal · 2022Article
- Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator.The Journal of pathology · 2022Article
- The Aged Lower Urinary Tract: Deficits in Neural Control Mechanisms.Frontiers in aging · 2021Review
- Botulinum toxin therapy in children with neurogenic detrusor overactivity.Turkish journal of urology · 2020Review
- The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.Therapeutic advances in urology · 2018Review
- Drugs for the overactive bladder: are there differences in persistence and compliance?Translational andrology and urology · 2017Article
- On the Site and Mechanism of Action of βInternational neurourology journal · 2017Review
- Article
- Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms.International journal of clinical and experimental pathology · 2015Article
- A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle.The Journal of pharmacology and experimental therapeutics · 2013Article
- β3-receptor agonists for overactive bladder--new frontier or more of the same?Current urology reports · 2013Review
- New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Therapeutics and clinical risk management · 2013Article
- Inhibitory effect of curcumin on the contractility of isolated caprine detrusor muscle.Indian journal of pharmaceutical sciencesArticle
- Neurogenic bladder - concepts and treatment recommendations.International braz j urol : official journal of the Brazilian Society of UrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overactive bladder syndrome and detrusor overactivity are conditions that can have major effects on quality of life and social functioning. Antimuscarinic drugs are still first-line treatment. These drugs often have good initial response rates, but adverse effects and decreasing efficacy cause long-term compliance problems, and alternatives are needed. The recognition of the functional contribution of the urothelium/suburothelium, the autonomous detrusor muscle activity during bladder filling and the diversity of nerve transmitters involved has sparked interest in both peripheral and central modulation of overactive bladder syndrome/detrusor overactivity pathophysiology. Three drugs recently approved for treatment of overactive bladder syndrome/detrusor overactivity (mirabegron, tadalafil and onabotulinum toxin A), representing different pharmacological mechanisms; that is, β-adrenoceptor agonism, phosphodiesterase type 5 inhibition, and inhibition of nerve release of efferent and afferent transmitters, all seem to have one effect in common: inhibition of the afferent nervous activity generated by the bladder during filling. In the present review, the different mechanisms forming the pharmacological basis for the use of these drugs are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.